Researchers warned that to achieve such reductions, greater uptake of the medication among indicated patients is needed.

Medicare Advantage updates while halting proposed anti-obesity drug coverage, impacting millions of potential beneficiaries.

The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...

A proposal by the Biden administration to cover weight-loss medicines for obesity under Medicare has been axed by the White ...

Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have become household names in recent ...

Additionally, after the FDA approved Wegovy (Semaglutide) for treating heart disease, including for those with obesity or overweight, Medicare plans may be able to cover it for those who require ...

Compounded semaglutide and Ozempic are different products. While both may be used in people with type 2 diabetes, Ozempic is approved by the FDA, but compounded semaglutide is not. Compounded ...

An analysis of differential coding patterns between Medicare Advantage (MA) and Traditional Medicare (TM) plans estimated how much coding differs between insurers and how much extra revenue insurers ...

You've probably heard of GLP-1s, a class of drugs that includes semaglutide (Ozempic). The drugs were developed to manage ...